ReviewAnnals of the rheumatic diseases2005
Psoriatic arthritis treatment: biological response modifiers.
Review in Annals of the rheumatic diseases, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 98 citations in OpenAlex.
- Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.Arthritis research & therapy · 2010Trial
- Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?Clinical rheumatology · 2017Article
- Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.Rheumatology and therapy · 2016Article
- Biologics in dermatology.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Measuring disease activity in psoriatic arthritis.International journal of rheumatology · 2012Article
- An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX).Clinical rheumatology · 2010Article
- Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine.Clinical rheumatology · 2008Article
- TNFalpha blockade in human diseases: an overview of efficacy and safety.Clinical immunology (Orlando, Fla.) · 2008Review
- Economic burden of psoriatic arthritis.PharmacoEconomics · 2008Review
- Adalimumab in the treatment of arthritis.Therapeutics and clinical risk management · 2007Article
- Etanercept: a review of its use in the management of ankylosing spondylitis and psoriatic arthritis.Drugs · 2007Review
- Infliximab (Remicade) in the treatment of psoriatic arthritis.Therapeutics and clinical risk management · 2006Article
- Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology.Current rheumatology reports · 2006Review
- Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.Annals of the rheumatic diseases · 2005Review
- Psoriatic arthritis assessment tools in clinical trials.Annals of the rheumatic diseases · 2005Review
- Psoriatic arthritis and imaging.Annals of the rheumatic diseases · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years there has been a surge of interest in the treatment of chronic inflammatory disorders as a result of the development and application of targeted biological therapies. The elucidation of the overlapping cellular and cytokine immunopathology of such diverse conditions as rheumatoid arthritis (RA), Crohn's disease, and psoriasis points to specific targets for bioengineered proteins or small molecules. Similar to clinical trials in RA, trials in psoriatic arthritis (PsA) have shown excellent clinical results with the tumour necrosis factor (TNF) blockers, etanercept, infliximab, and adalimumab in a variety of domains including the joints, quality of life, function, and slowing of disease progress as evidenced radiologically. In addition, these agents have shown benefit in domains more unique to PsA, such as the skin lesions of psoriasis, enthesitis, and dactylitis, pointing out the similar pathogenesis of the disease in the skin, the tendons, and the synovial membrane. This therapy has been generally safe and well tolerated in clinical trials of PsA. Other logical candidates for targeted therapy in development include other anti-TNF agents, costimulatory blockade agents that affect T cell function, blockers of other cytokines such as interleukin (IL)-1, 6, 12, 15, or 18, and B cell modulatory medicines. Also, it will be useful to learn more about the effects of combining traditional disease modifying drugs and the newer biologicals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.